Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Histopathology
    July 2026
  1. MARABI M, Li Y, Aphivatanasiri C, Tsang JY, et al
    Calcification and tumour-infiltrating lymphocytes predict upgrade of human epidermal growth factor 2 (HER2)-negative ductal carcinoma in situ diagnosed on core needle biopsy.
    Histopathology. 2026;89:122-135.
    >> Share

  2. KOSHY R, Jain PV, Jorns JM
    Characterizing pseudoangiomatous stromal hyperplasia (PASH) of the breast.
    Histopathology. 2026;89:174-180.
    >> Share

    June 2026
  3. LIU L, Graff SL, Hacking S, Cheng L, et al
    Genomic and clinicopathological characteristics of low oncotype recurrent score breast cancers with subsequent metastasis.
    Histopathology. 2026;88:1451-1458.
    >> Share

    May 2026
  4. PANG JB, Gorringe KL, Tan PH, Fox SB, et al
    Molecular pathology of phyllodes tumours of the breast-much more than MED12.
    Histopathology. 2026;88:1115-1125.
    >> Share

  5. INGYIN H, Solomon JP, Li Y, Xu D, et al
    Genetic and immunohistochemical studies identify recurrent ACTB mutations and PTEN alterations in tubular adenomas of the breast.
    Histopathology. 2026;88:1229-1235.
    >> Share

  6. KRINGS G, Hashem S, Apushkin MA, Ang-Rabanes TL, et al
    Tall cell carcinoma with reversed polarity of the breast harbouring IDH1 hotspot mutation: morphologic, immunohistochemical and genetic characterization of two cases.
    Histopathology. 2026;88:1212-1220.
    >> Share

    April 2026
  7. SHEPHERD DJ, Craig C, Valencia-Guerrero AL, Chattu S, et al
    Prostein (p501s) is expressed in primary extramammary Paget disease.
    Histopathology. 2026;88:1094-1098.
    >> Share

  8. MISRA S, Gudi M, Allison KH, Brogi E, et al
    Mucin-producing breast lesions: a practical approach to diagnosis.
    Histopathology. 2026;88:939-957.
    >> Share

  9. ZUO K, Shui R, Xu X, Yu B, et al
    Apocrine encapsulated papillary carcinoma: a comprehensive clinicopathological analysis of 28 cases.
    Histopathology. 2026;88:1075-1083.
    >> Share

    March 2026

  10. Correction to 'A simple digital image analysis system for automated Ki67 assessment in primary breast cancer'.
    Histopathology. 2026 Mar 11. doi: 10.1111/his.70123.
    >> Share

  11. RAKHA EA, Tan PH, Raymond WA
    The spectrum of breast in situ papillary carcinomas with invasion and invasive breast carcinomas with papillary features: an overview of histological subtypes and diagnostic challenges.
    Histopathology. 2026;88:747-768.
    >> Share

  12. NAKAMURA H, Kukita Y, Kittaka N, Kusama H, et al
    Apocrine carcinoma of the breast: distinctive metabolic reprogramming and high-frequency PIK3CA mutations revealed by molecular and immunohistochemical analysis.
    Histopathology. 2026;88:790-809.
    >> Share

    February 2026
  13. D'ARRIGO C, Tuzlali S, Barroso-Sousa R, El Saghir NS, et al
    Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study.
    Histopathology. 2026 Feb 22. doi: 10.1111/his.70091.
    >> Share

  14. LLEWELLYN A, Brown A, Morel J, Naidoo K, et al
    To VAE or not to VAE: outcomes of radial scars/complex sclerosing lesions and papillary lesions without atypia in the King's College Hospital breast service (2017-2023).
    Histopathology. 2026;88:583-590.
    >> Share

    January 2026
  15. HUANG CY, Wang YJ, Hsieh MS, Lin PY, et al
    Tumour-infiltrating lymphocytes, tertiary lymphoid structures and myxoid stroma predict upstaging of ductal carcinoma in situ in breast biopsies.
    Histopathology. 2026;88:471-487.
    >> Share

  16. YE Q, Estrella J, Kalhor N, Liu A, et al
    TRPS1 expression in neuroendocrine neoplasms of breast and other organs.
    Histopathology. 2026;88:524-532.
    >> Share

    December 2025
  17. KAIN ZE, Baez-Navarro X, Linn SC, van Deurzen CHM, et al
    Decision-making in breast pathology reporting: the effect of clinical relevant thresholds.
    Histopathology. 2025;87:951-955.
    >> Share

  18. SUN M, Fu L, Ren H, Wang J, et al
    Two similar but distinct types of breast acinar cell carcinoma: evidence from histological, immunohistochemical and molecular features.
    Histopathology. 2025;87:904-914.
    >> Share

  19. STA INES FM, Eadara A, Quddus MR, Sung CJ, et al
    Re-appraisal of mucocele-like lesion of the breast with atypia: study of 34 cases with focus on impact of type and extent of atypia on upgrade.
    Histopathology. 2025;87:943-950.
    >> Share

    September 2025
  20. MAKHLOUF S, Almalki N, Sheha A, Atallah NM, et al
    Outcome prediction of oestrogen receptor-positive breast cancer based on a panel of oestrogen receptor-regulated genes.
    Histopathology. 2025 Sep 12. doi: 10.1111/his.15557.
    >> Share

    August 2025
  21. SALISBURY T, Rendi M, Bhalli R, Bean GR, et al
    DCIS-like invasive carcinoma of the breast with tumour-associated microvasculature mimicking myoepithelium: a diagnostic pitfall.
    Histopathology. 2025;87:246-257.
    >> Share

  22. HAN R, Hashmi AA, Wen HY, Murray M, et al
    Clinicopathological features of microinvasive lobular carcinoma.
    Histopathology. 2025;87:235-245.
    >> Share

  23. TAN PH, Ellis IO, Allison KH, Badve SS, et al
    Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria.
    Histopathology. 2025;87:169-182.
    >> Share

    July 2025
  24. LEE AHS, Rakha EA, Hodi Z, Abbas A, et al
    Retesting of oestrogen receptor, progesterone receptor and HER2 status of invasive carcinoma of the breast after neoadjuvant chemotherapy.
    Histopathology. 2025;87:58-67.
    >> Share

    June 2025
  25. LAOKULRATH N, Nasir NDM, Gudi M, Tan PH, et al
    Diagnostic accuracy and challenges of intraoperative frozen section evaluation for axillary sentinel lymph node biopsy and breast margins.
    Histopathology. 2025;86:1121-1136.
    >> Share

  26. AL-REFAI R, Ali A, Roychoudhury S, Bendari A, et al
    Male breast atypical ductal hyperplasia (ADH): clinicopathological insights from a rare cohort.
    Histopathology. 2025;86:1137-1146.
    >> Share

    May 2025
  27. SOKOLOVA A, Joshi V, Chittoory H, Walsh M, et al
    ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection.
    Histopathology. 2025 May 13. doi: 10.1111/his.15465.
    >> Share

  28. EL SHEIKH S, Mansour MA, Provenzano E, Shaaban A, et al
    Diagnostic interobserver variability of atypia assessment in columnar cell lesions among a group of expert breast pathologists in the United Kingdom and the Republic of Ireland, on behalf of the UK national coordinating committee for breast pathology.
    Histopathology. 2025;86:953-966.
    >> Share

  29. HONG R, Wang H, Lin Y, Yin X, et al
    The clinicopathological and molecular features of primary high-grade neuroendocrine tumour in the breast.
    Histopathology. 2025;86:900-915.
    >> Share

    April 2025
  30. BOYRAZ B, Robinson B, Lindeman N, Hoda SA, et al
    Subareolar sclerosing ductal hyperplasia shows PI3K pathway alterations.
    Histopathology. 2025;86:824-827.
    >> Share

  31. KHEDR M, Gandhi S, Roy AM, Alharbi M, et al
    Breast biomarkers evolution between primary and distant metastasis: incidence and significance.
    Histopathology. 2025;86:793-804.
    >> Share

  32. KATAYAMA A, Makhlouf S, Toss MS, Oyama T, et al
    Nuclear morphological characterisation of lobular carcinoma variants: a morphometric study.
    Histopathology. 2025;86:813-823.
    >> Share

  33. KRINGS G, Shamir ER, Lae M, Bean GR, et al
    Serous-like breast carcinomas: immunophenotypic, genetic, and clinicopathologic characterization of a morphologically distinct group of tumours.
    Histopathology. 2025;86:779-792.
    >> Share

  34. YANG E, Fineberg S, Mohamed A, Brogi E, et al
    Variability in the diagnosis and reporting of metaplastic breast carcinoma: results of an international survey.
    Histopathology. 2025;86:742-749.
    >> Share

    March 2025
  35. KIM M, Lee M, Lee A, Choi BO, et al
    Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple-negative breast cancer.
    Histopathology. 2025 Mar 31. doi: 10.1111/his.15453.
    >> Share

  36. CHAN R, Leung H, Li J, Poon I, et al
    Evaluation of breast-specific marker expression in metastatic breast cancers: Correlation with subtype switch.
    Histopathology. 2025;86:536-546.
    >> Share

  37. RAKHA EA, Quinn C
    Controversies regarding encapsulated papillary carcinoma of the breast: an approach to evaluation and categorisation.
    Histopathology. 2025;86:497-513.
    >> Share

    February 2025
  38. AI D, Arrey EN, Postlewait LM, Gao Y, et al
    The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response.
    Histopathology. 2025 Feb 4. doi: 10.1111/his.15417.
    >> Share

  39. YANG E, D'Alfonso TM, Morrow M, Brogi E, et al
    Discordance of human epidermal growth factor receptor 2-low status between breast primary and distant metastases with clinical-pathological correlation.
    Histopathology. 2025;86:441-449.
    >> Share

  40. TAHA SR, Boulos F
    E-cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes.
    Histopathology. 2025;86:327-340.
    >> Share

    January 2025
  41. ASHI A, Awaji AA, Bond J, Johnson CA, et al
    Threonine and tyrosine kinase (TTK) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting.
    Histopathology. 2025 Jan 7. doi: 10.1111/his.15399.
    >> Share

  42. LEE AHS, Hodi Z, Abbas A, Ellis IO, et al
    HER2-positive grade 1 invasive carcinomas of the breast.
    Histopathology. 2025;86:278-284.
    >> Share

    December 2024
  43. WANG Y, Liu L, Graff SL, Cheng L, et al
    Recent advancements in biomarkers and molecular diagnostics in hormonal receptor-positive breast cancer.
    Histopathology. 2024 Dec 17. doi: 10.1111/his.15395.
    >> Share

  44. ONAGI H, Horimoto Y, Okano S, Sasa K, et al
    Clinicopathological characteristics of Japanese patients with breast cancer and MET exon 14 skipping alterations.
    Histopathology. 2024 Dec 4. doi: 10.1111/his.15382.
    >> Share

  45. HEMPENIUS MA, Eenkhoorn MA, Hoeg H, Dabbs DJ, et al
    Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study.
    Histopathology. 2024;85:920-928.
    >> Share

    October 2024
  46. MATSUMOTO H, Miyata R, Tsuruta Y, Nakada N, et al
    Ki-67 evaluation using deep-learning model-assisted digital image analysis in breast cancer.
    Histopathology. 2024 Oct 31. doi: 10.1111/his.15356.
    >> Share

  47. WANG Y, Liu L, Graff SL, Cheng L, et al
    Locoregional event or dyssynchronous distant metastasis: clinicopathological and molecular analysis of contralateral axillary lymph node metastasis in breast cancer patients.
    Histopathology. 2024 Oct 22. doi: 10.1111/his.15345.
    >> Share

    September 2024
  48. WONG CJW, Md Nasir ND, Koh VCY, Campbell F, et al
    Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast.
    Histopathology. 2024;85:510-520.
    >> Share

  49. BATRA H, Bose PSC, Ding Y, Dai A, et al
    MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers.
    Histopathology. 2024;85:503-509.
    >> Share

  50. TURASHVILI G
    Nonneoplastic and neoplastic sclerosing lesions of the breast.
    Histopathology. 2024;85:383-396.
    >> Share

  51. GRABENSTETTER A, Brennan SB, Jochelson MS, Brogi E, et al
    Radial sclerosing lesions found on core needle biopsy: excision can be safely avoided.
    Histopathology. 2024;85:397-404.
    >> Share

  52. ELLIS I, Webster F, Allison KH, Dang C, et al
    Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;85:418-436.
    >> Share

    August 2024
  53. ZWAGER MC, Yu S, Buikema HJ, de Bock GH, et al
    Advancing Ki67 hotspot detection in breast cancer: a comparative analysis of automated digital image analysis algorithms.
    Histopathology. 2024 Aug 5. doi: 10.1111/his.15294.
    >> Share

    July 2024
  54. BANNIER PA, Broeckx G, Herpin L, Dubois R, et al
    Development of a deep-learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2-low cases.
    Histopathology. 2024 Jul 14. doi: 10.1111/his.15274.
    >> Share

  55. TOZBIKIAN G, Bui MM, Hicks DG, Jaffer S, et al
    Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists.
    Histopathology. 2024 Jul 8. doi: 10.1111/his.15275.
    >> Share

  56. ZHANG H, Finkelman BS, Ettel MG, Velez MJ, et al
    HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
    Histopathology. 2024;85:3-19.
    >> Share

    June 2024
  57. LASHEN AG, Toss M, Miligy I, Rewcastle E, et al
    Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study.
    Histopathology. 2024 Jun 13. doi: 10.1111/his.15234.
    >> Share

  58. MILIGY IM, Awasthi R, Mir Y, Khurana A, et al
    Morphological and molecular changes of oestrogen receptor-positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study.
    Histopathology. 2024 Jun 7. doi: 10.1111/his.15238.
    >> Share

  59. LAOKULRATH N, Gudi M, Salahuddin SA, Chong APY, et al
    Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
    Histopathology. 2024 Jun 6. doi: 10.1111/his.15213.
    >> Share

  60. BOSSUYT V, Provenzano E, Symmans WF, Webster F, et al
    A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;84:1111-1129.
    >> Share

    May 2024
  61. LI J, Dong P, Wang X, Zhang J, et al
    Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
    Histopathology. 2024 May 15. doi: 10.1111/his.15205.
    >> Share

  62. HUANG CY, Chang RF, Lin CY, Hsieh MS, et al
    Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
    Histopathology. 2024;84:983-1002.
    >> Share

    April 2024
  63. BADR NM, Zaakouk M, Zhang Q, Kearns D, et al
    Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Histopathology. 2024 Apr 23. doi: 10.1111/his.15193.
    >> Share

  64. LI JJX, Ni SYB, Tsang JYS, Chan WY, et al
    Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy.
    Histopathology. 2024;84:810-821.
    >> Share

  65. ALKHAYYAT R, Abbas A, Quinn CM, Rakha EA, et al
    Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Histopathology. 2024;84:723-741.
    >> Share

  66. AZAM AS, Tsang YW, Thirlwall J, Kimani PK, et al
    Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
    Histopathology. 2024;84:847-862.
    >> Share

    March 2024
  67. LY A, Garcia V, Blenman KRM, Ehinger A, et al
    Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
    Histopathology. 2024 Mar 3. doi: 10.1111/his.15140.
    >> Share

    November 2023
  68. CSERNI G, Kalman E, Udvarhelyi N, Papp E, et al
    Evaluation of the routine use of E-cadherin immunohistochemistry in the typing of breast carcinomas: results of a randomized diagnostic study.
    Histopathology. 2023;83:810-821.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016